newsfilter
← Latest News
PR Newswire·

NCCN Guidelines® Recommend VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

VONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count SEATTLE, April 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that VONJO™ (pacritinib), its novel oral